215 related articles for article (PubMed ID: 20094015)
1. Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone.
Valen-Sendstad A; Engedal K; Stray-Pedersen B; ; Strobel C; Barnett L; Meyer N; Nurminemi M
Am J Geriatr Psychiatry; 2010 Jan; 18(1):11-20. PubMed ID: 20094015
[TBL] [Abstract][Full Text] [Related]
2. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W
Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877
[TBL] [Abstract][Full Text] [Related]
3. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
[TBL] [Abstract][Full Text] [Related]
4. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
[TBL] [Abstract][Full Text] [Related]
5. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.
Devanand DP; Pelton GH; Zamora D; Liu X; Tabert MH; Goodkind M; Scarmeas N; Braun I; Stern Y; Mayeux R
Arch Neurol; 2005 Jun; 62(6):975-80. PubMed ID: 15956169
[TBL] [Abstract][Full Text] [Related]
6. Estrogen + progestin therapy and cognition: a randomized placebo-controlled double-blind study.
Alhola P; Tuomisto H; Saarinen R; Portin R; Kalleinen N; Polo-Kantola P
J Obstet Gynaecol Res; 2010 Aug; 36(4):796-802. PubMed ID: 20666948
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.
Kleiman T; Zdanys K; Black B; Rightmer T; Grey M; Garman K; Macavoy M; Gelernter J; van Dyck C
Dement Geriatr Cogn Disord; 2006; 22(1):73-82. PubMed ID: 16699282
[TBL] [Abstract][Full Text] [Related]
8. A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women.
Tierney MC; Oh P; Moineddin R; Greenblatt EM; Snow WG; Fisher RH; Iazzetta J; Hyslop PS; MacLusky NJ
Psychoneuroendocrinology; 2009 Aug; 34(7):1065-74. PubMed ID: 19297102
[TBL] [Abstract][Full Text] [Related]
9. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS.
Lyketsos CG; DelCampo L; Steinberg M; Miles Q; Steele CD; Munro C; Baker AS; Sheppard JM; Frangakis C; Brandt J; Rabins PV
Arch Gen Psychiatry; 2003 Jul; 60(7):737-46. PubMed ID: 12860778
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
[TBL] [Abstract][Full Text] [Related]
11. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease.
Hoyt BD; Massman PJ; Schatschneider C; Cooke N; Doody RS
Arch Neurol; 2005 Mar; 62(3):454-9. PubMed ID: 15767511
[TBL] [Abstract][Full Text] [Related]
12. A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life.
Almeida OP; Lautenschlager NT; Vasikaran S; Leedman P; Gelavis A; Flicker L
Neurobiol Aging; 2006 Jan; 27(1):141-9. PubMed ID: 16298249
[TBL] [Abstract][Full Text] [Related]
13. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
[TBL] [Abstract][Full Text] [Related]
14. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.
Panisset M; Gauthier S; Moessler H; Windisch M;
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1089-104. PubMed ID: 12111446
[TBL] [Abstract][Full Text] [Related]
15. The apolipoprotein E epsilon4 allele and antidepressant efficacy in cognitively intact elderly depressed patients.
Murphy GM; Kremer C; Rodrigues H; Schatzberg AF;
Biol Psychiatry; 2003 Oct; 54(7):665-73. PubMed ID: 14512205
[TBL] [Abstract][Full Text] [Related]
16. The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease.
Rigaud AS; Traykov L; Caputo L; Guelfi MC; Latour F; Couderc R; Moulin F; de Rotrou J; Forette F; Boller F
Eur J Neurol; 2000 May; 7(3):255-8. PubMed ID: 10886308
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial.
Soares CN; Almeida OP; Joffe H; Cohen LS
Arch Gen Psychiatry; 2001 Jun; 58(6):529-34. PubMed ID: 11386980
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
19. The APOE polymorphism in Alzheimer's disease patients with neuropsychiatric symptoms and syndromes.
D'Onofrio G; Panza F; Seripa D; Sancarlo D; Paris F; Cascavilla L; Urbano M; Gravina C; Fontana A; Solfrizzi V; Pellegrini F; Pilotto A
Int J Geriatr Psychiatry; 2011 Oct; 26(10):1062-70. PubMed ID: 21905100
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
